An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers (Q30395583)

21 June 2017

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers (English)

1 reference

21 June 2017

0 references

1 reference

1 reference

13

Rebecca J Cox

1 reference

21 June 2017

Abdullah S Madhun

1

1 reference

21 June 2017

Per Espen Akselsen

2

1 reference

21 June 2017

Haakon Sjursen

3

1 reference

21 June 2017

Gabriel Pedersen

4

1 reference

21 June 2017

Signe Svindland

5

1 reference

21 June 2017

Jane Kristin Nøstbakken

6

1 reference

21 June 2017

Mona Nilsen

7

1 reference

21 June 2017

Kristin Mohn

8

1 reference

21 June 2017

Asne Jul-Larsen

9

1 reference

21 June 2017

Ingrid Smith

10

1 reference

21 June 2017

Diane Major

11

1 reference

21 June 2017

John Wood

12

1 reference

21 June 2017

language of work or name

English

0 references

publication date

27 October 2010

1 reference

21 June 2017

1 reference

21 June 2017

29

1 reference

21 June 2017

2

1 reference

21 June 2017

266-273

1 reference

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Response to a monovalent 2009 influenza A (H1N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Parenteral influenza vaccination induces a rapid systemic and local immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Reproducibility of serologic assays for influenza virus A (H5N1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.038

10.1016/J.VACCINE.2010.10.038

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference